Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antibody Therapy With Alemtuzumab, Rituximab and GM-CSF for Initial Treatment of High Risk Chronic Lymphocytic Leukemia

NCT00562328 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00562328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00562328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antibody Therapy With Alemtuzumab, Rituximab and GM-CSF for Initial Treatment of High Risk Chronic Lymphocytic Leukemia
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
December 18, 2014
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia